spacer
home > ebr > autumn 2017 > size matters
PUBLICATIONS
European Biopharmaceutical Review

Size Matters

Progressive research in gene and cell therapy, as well as DNA vaccination, requires safe pharmaceutical vectors. The former, in particular, is on the rise, with a huge potential for treating inherited disorders. However, the advances in this area depend on improved vector designs, which enable the safe delivery of therapeutics into target cells (1). The novel transfer vectors should be direct, tissue-specific, stable and highly expressive. They have to be minimally toxic, regarding anti-vector immune responses, and should not be integrated into the host genome (2). Without integration, the toxicity is low, but this also means that long-term expression – and thus therapeutic effect in mitotic cells – may not occur because of progressive loss of vector DNA (2).

Usually, viral and non-viral vectors based on plasmid DNA are used for the transfer of genetic information into the target cells. Plasmids encode these on the intracellular production of therapeutic virus particles (3). Clinical use of plasmid DNA for gene or cell therapy, as well as genetic vaccination, has been in an inferior position to viral methods, but has made significant progress in recent years (4,5).

Challenging Transfers

One limiting factor in transgene expression is the transfer process into the cytoplasm and nucleus, as the size of the DNA is crucial (6,7). The smaller it is, the better the nuclear entry. The differing proportions between two otherwise identical plasmids, such as monomer and dimer, show the influence of this procedure (8).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Tatjana Buchholz is a certified Medical Technical Laboratory Assistant. She also has a Bachelor of Science in molecular biotechnology and a Master of Science in genome-based systems biology from the Bielefeld University, Germany. Tatjana’s bachelor’s thesis was occupied with signal studies of the promoter activity of the nuclear LHC translational repressor NAB1 in the microalgae chlamydomonas reinhardtii, and her master’s thesis was concerned with MC technology optimisation. Tatjana joined PlasmidFactory as Marketing Manager in 2016.

Dr Marco Schmeer studied chemistry and holds a PhD from the University of Bielefeld, Germany. After further postdoctoral training in the fields of electroporative gene and drug transfer, he joined PlasmidFactory as Product and Project Manager in 2005, when he was made responsible for client-related plasmid and MC production projects.

Dr Martin Schleef studied biology at the universities Würzburg and Bielefeld, Germany, and holds a PhD from the latter. He received postdoctoral training from the Institut Pasteur Paris, France, and joined QIAGEN GmbH in Hilden, Germany, in 1994. Martin is founder and CEO of PlasmidFactory, which has been a prosperous biotech company in Bielefeld since 2000. He is also a lecturer at Bielefeld University.

spacer
Tatjana Buchholz
spacer
spacer
spacer
Dr Marco Schmeer
spacer
spacer
spacer
Dr Martin Schleef
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

YHEC announces the promotions of Michelle Jenks and Rachael McCool to the role Project Director

YHEC is pleased to announce the promotions of Michelle Jenks from the Economic Modelling team and Rachael McCool from the Systematic Reviewing team to the role Project Director. Michelle has a Master’s degree (MSc) in health economics from the University of York and has conducted economic evaluations and systematic reviews for both public and private sector clients. Michelle is the lead modeller in YHEC’s role as an External Assessment Centre for NICE and has also led on a range of economic evaluations conducted for clients within industry, such as cost-utility models and budget impact models. She often leads the development of early economic analyses to inform clinical trial design and pricing strategy.
More info >>

White Papers

Investigator Portals: Facilitating and Streamlining Communication & Collaboration with Study Sites

ArisGlobal

ArisGlobal LLC Investigator site personnel are often frustrated with the lack of transparency and communication with their sponsors, leading to significant dissatisfaction and withdrawal from current and future studies. The adoption of investigator portals gives sponsors a platform that fosters collaboration and improves site management. Learn about five key areas of sponsor-investigator site interactions deserving of electronic communication and collaboration. Technology and design aspects are also covered.
More info >>

 
Industry Events

3rd Annual Inhalation & Respiratory Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 3rd Annual Inhalation & Respiratory Drug Delivery Congress, 8th – 9th May 2018, London, UK. Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 20 presentations and case studies focused on the key issues in inhalation and respiratory drug delivery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement